Serveur d'exploration Chloroquine

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Enhanced autophagy is required for survival in EGFR-independent EGFR-mutant lung adenocarcinoma cells.

Identifieur interne : 001116 ( Main/Exploration ); précédent : 001115; suivant : 001117

Enhanced autophagy is required for survival in EGFR-independent EGFR-mutant lung adenocarcinoma cells.

Auteurs : Yuji Sakuma [Japon] ; Shoichi Matsukuma ; Yoshiyasu Nakamura ; Mitsuyo Yoshihara ; Shiro Koizume ; Hironobu Sekiguchi ; Haruhiro Saito ; Haruhiko Nakayama ; Yoichi Kameda ; Tomoyuki Yokose ; Sachiko Oguni ; Toshiro Niki ; Yohei Miyagi

Source :

RBID : pubmed:23938604

Descripteurs français

English descriptors

Abstract

Lung cancers harboring epidermal growth factor receptor (EGFR) mutations depend on constitutive activation of the kinase for survival. Although most EGFR-mutant lung cancers are sensitive to EGFR tyrosine kinase inhibitors (TKIs) and shrink in response to treatment, acquired resistance to TKI therapy is common. We demonstrate here that two EGFR-mutated lung adenocarcinoma cell lines, HCC827 and HCC4006, contain a subpopulation of cells that have undergone epithelial-to-mesenchymal transition and survive independent of activated EGFR. These EGFR-independent cancer cells, herein termed gefitinib-resistant (GR) cells, demonstrate higher levels of basal autophagy than their parental cells and thrive under hypoxic, reduced-serum conditions in vitro; this somewhat simulates the hypoxic environment common to cancerous tissues. We show that depletion of the essential autophagy gene, ATG5, by small interfering RNA (siRNA) or chloroquine, an autophagy inhibitor, markedly reduces GR cell viability under hypoxic conditions. Moreover, we show a significant elevation in caspase activity in GR cells following knockdown of ATG5. These results suggest that GR cells can evade apoptosis and survive in hostile, hypoxic environments with constant autophagic flux. We also show the presence of autophagosomes in some cancer cells from patient samples, even in untreated EGFR-mutant lung cancer tissue samples. Together, our results indicate that autophagy inhibitors alone or in combination with EGFR TKIs may be an effective approach for the treatment of EGFR-mutant lung cancers, where basal autophagy of some cancer cells is upregulated.

DOI: 10.1038/labinvest.2013.102
PubMed: 23938604


Affiliations:


Links toward previous steps (curation, corpus...)


Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">Enhanced autophagy is required for survival in EGFR-independent EGFR-mutant lung adenocarcinoma cells.</title>
<author>
<name sortKey="Sakuma, Yuji" sort="Sakuma, Yuji" uniqKey="Sakuma Y" first="Yuji" last="Sakuma">Yuji Sakuma</name>
<affiliation wicri:level="1">
<nlm:affiliation>1] Molecular Pathology and Genetics Division, Kanagawa Cancer Center Research Institute, Yokohama, Japan [2] Laboratory for Molecular Diagnostics, Kanagawa Cancer Center Hospital, Yokohama, Japan [3] Department of Pathology, Jichi Medical University, Tochigi, Japan.</nlm:affiliation>
<country xml:lang="fr">Japon</country>
<wicri:regionArea>1] Molecular Pathology and Genetics Division, Kanagawa Cancer Center Research Institute, Yokohama, Japan [2] Laboratory for Molecular Diagnostics, Kanagawa Cancer Center Hospital, Yokohama, Japan [3] Department of Pathology, Jichi Medical University, Tochigi</wicri:regionArea>
<wicri:noRegion>Tochigi</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Matsukuma, Shoichi" sort="Matsukuma, Shoichi" uniqKey="Matsukuma S" first="Shoichi" last="Matsukuma">Shoichi Matsukuma</name>
</author>
<author>
<name sortKey="Nakamura, Yoshiyasu" sort="Nakamura, Yoshiyasu" uniqKey="Nakamura Y" first="Yoshiyasu" last="Nakamura">Yoshiyasu Nakamura</name>
</author>
<author>
<name sortKey="Yoshihara, Mitsuyo" sort="Yoshihara, Mitsuyo" uniqKey="Yoshihara M" first="Mitsuyo" last="Yoshihara">Mitsuyo Yoshihara</name>
</author>
<author>
<name sortKey="Koizume, Shiro" sort="Koizume, Shiro" uniqKey="Koizume S" first="Shiro" last="Koizume">Shiro Koizume</name>
</author>
<author>
<name sortKey="Sekiguchi, Hironobu" sort="Sekiguchi, Hironobu" uniqKey="Sekiguchi H" first="Hironobu" last="Sekiguchi">Hironobu Sekiguchi</name>
</author>
<author>
<name sortKey="Saito, Haruhiro" sort="Saito, Haruhiro" uniqKey="Saito H" first="Haruhiro" last="Saito">Haruhiro Saito</name>
</author>
<author>
<name sortKey="Nakayama, Haruhiko" sort="Nakayama, Haruhiko" uniqKey="Nakayama H" first="Haruhiko" last="Nakayama">Haruhiko Nakayama</name>
</author>
<author>
<name sortKey="Kameda, Yoichi" sort="Kameda, Yoichi" uniqKey="Kameda Y" first="Yoichi" last="Kameda">Yoichi Kameda</name>
</author>
<author>
<name sortKey="Yokose, Tomoyuki" sort="Yokose, Tomoyuki" uniqKey="Yokose T" first="Tomoyuki" last="Yokose">Tomoyuki Yokose</name>
</author>
<author>
<name sortKey="Oguni, Sachiko" sort="Oguni, Sachiko" uniqKey="Oguni S" first="Sachiko" last="Oguni">Sachiko Oguni</name>
</author>
<author>
<name sortKey="Niki, Toshiro" sort="Niki, Toshiro" uniqKey="Niki T" first="Toshiro" last="Niki">Toshiro Niki</name>
</author>
<author>
<name sortKey="Miyagi, Yohei" sort="Miyagi, Yohei" uniqKey="Miyagi Y" first="Yohei" last="Miyagi">Yohei Miyagi</name>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">PubMed</idno>
<date when="2013">2013</date>
<idno type="RBID">pubmed:23938604</idno>
<idno type="pmid">23938604</idno>
<idno type="doi">10.1038/labinvest.2013.102</idno>
<idno type="wicri:Area/PubMed/Corpus">000330</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000330</idno>
<idno type="wicri:Area/PubMed/Curation">000330</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000330</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000327</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000327</idno>
<idno type="wicri:Area/Ncbi/Merge">000209</idno>
<idno type="wicri:Area/Ncbi/Curation">000209</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000209</idno>
<idno type="wicri:Area/Main/Merge">001117</idno>
<idno type="wicri:Area/Main/Curation">001116</idno>
<idno type="wicri:Area/Main/Exploration">001116</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en">Enhanced autophagy is required for survival in EGFR-independent EGFR-mutant lung adenocarcinoma cells.</title>
<author>
<name sortKey="Sakuma, Yuji" sort="Sakuma, Yuji" uniqKey="Sakuma Y" first="Yuji" last="Sakuma">Yuji Sakuma</name>
<affiliation wicri:level="1">
<nlm:affiliation>1] Molecular Pathology and Genetics Division, Kanagawa Cancer Center Research Institute, Yokohama, Japan [2] Laboratory for Molecular Diagnostics, Kanagawa Cancer Center Hospital, Yokohama, Japan [3] Department of Pathology, Jichi Medical University, Tochigi, Japan.</nlm:affiliation>
<country xml:lang="fr">Japon</country>
<wicri:regionArea>1] Molecular Pathology and Genetics Division, Kanagawa Cancer Center Research Institute, Yokohama, Japan [2] Laboratory for Molecular Diagnostics, Kanagawa Cancer Center Hospital, Yokohama, Japan [3] Department of Pathology, Jichi Medical University, Tochigi</wicri:regionArea>
<wicri:noRegion>Tochigi</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Matsukuma, Shoichi" sort="Matsukuma, Shoichi" uniqKey="Matsukuma S" first="Shoichi" last="Matsukuma">Shoichi Matsukuma</name>
</author>
<author>
<name sortKey="Nakamura, Yoshiyasu" sort="Nakamura, Yoshiyasu" uniqKey="Nakamura Y" first="Yoshiyasu" last="Nakamura">Yoshiyasu Nakamura</name>
</author>
<author>
<name sortKey="Yoshihara, Mitsuyo" sort="Yoshihara, Mitsuyo" uniqKey="Yoshihara M" first="Mitsuyo" last="Yoshihara">Mitsuyo Yoshihara</name>
</author>
<author>
<name sortKey="Koizume, Shiro" sort="Koizume, Shiro" uniqKey="Koizume S" first="Shiro" last="Koizume">Shiro Koizume</name>
</author>
<author>
<name sortKey="Sekiguchi, Hironobu" sort="Sekiguchi, Hironobu" uniqKey="Sekiguchi H" first="Hironobu" last="Sekiguchi">Hironobu Sekiguchi</name>
</author>
<author>
<name sortKey="Saito, Haruhiro" sort="Saito, Haruhiro" uniqKey="Saito H" first="Haruhiro" last="Saito">Haruhiro Saito</name>
</author>
<author>
<name sortKey="Nakayama, Haruhiko" sort="Nakayama, Haruhiko" uniqKey="Nakayama H" first="Haruhiko" last="Nakayama">Haruhiko Nakayama</name>
</author>
<author>
<name sortKey="Kameda, Yoichi" sort="Kameda, Yoichi" uniqKey="Kameda Y" first="Yoichi" last="Kameda">Yoichi Kameda</name>
</author>
<author>
<name sortKey="Yokose, Tomoyuki" sort="Yokose, Tomoyuki" uniqKey="Yokose T" first="Tomoyuki" last="Yokose">Tomoyuki Yokose</name>
</author>
<author>
<name sortKey="Oguni, Sachiko" sort="Oguni, Sachiko" uniqKey="Oguni S" first="Sachiko" last="Oguni">Sachiko Oguni</name>
</author>
<author>
<name sortKey="Niki, Toshiro" sort="Niki, Toshiro" uniqKey="Niki T" first="Toshiro" last="Niki">Toshiro Niki</name>
</author>
<author>
<name sortKey="Miyagi, Yohei" sort="Miyagi, Yohei" uniqKey="Miyagi Y" first="Yohei" last="Miyagi">Yohei Miyagi</name>
</author>
</analytic>
<series>
<title level="j">Laboratory investigation; a journal of technical methods and pathology</title>
<idno type="eISSN">1530-0307</idno>
<imprint>
<date when="2013" type="published">2013</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Adenocarcinoma (drug therapy)</term>
<term>Adenocarcinoma (genetics)</term>
<term>Adenocarcinoma (metabolism)</term>
<term>Adenocarcinoma (ultrastructure)</term>
<term>Adenocarcinoma of Lung</term>
<term>Adult</term>
<term>Aged</term>
<term>Antineoplastic Agents (pharmacology)</term>
<term>Autophagy (drug effects)</term>
<term>Autophagy-Related Protein 5</term>
<term>Cell Hypoxia (drug effects)</term>
<term>Cell Line, Tumor</term>
<term>Cell Survival</term>
<term>Drug Resistance, Neoplasm</term>
<term>Epithelial-Mesenchymal Transition</term>
<term>ErbB Receptors (antagonists & inhibitors)</term>
<term>ErbB Receptors (genetics)</term>
<term>ErbB Receptors (metabolism)</term>
<term>Female</term>
<term>Humans</term>
<term>Lung (drug effects)</term>
<term>Lung (metabolism)</term>
<term>Lung (pathology)</term>
<term>Lung Neoplasms (drug therapy)</term>
<term>Lung Neoplasms (genetics)</term>
<term>Lung Neoplasms (metabolism)</term>
<term>Lung Neoplasms (ultrastructure)</term>
<term>Male</term>
<term>Microtubule-Associated Proteins (antagonists & inhibitors)</term>
<term>Microtubule-Associated Proteins (genetics)</term>
<term>Microtubule-Associated Proteins (metabolism)</term>
<term>Mutant Proteins (antagonists & inhibitors)</term>
<term>Mutant Proteins (metabolism)</term>
<term>Neoplasm Proteins (antagonists & inhibitors)</term>
<term>Neoplasm Proteins (genetics)</term>
<term>Neoplasm Proteins (metabolism)</term>
<term>Phagosomes (drug effects)</term>
<term>Phagosomes (metabolism)</term>
<term>Phagosomes (ultrastructure)</term>
<term>Protein Kinase Inhibitors (pharmacology)</term>
<term>RNA Interference</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr">
<term>Adulte</term>
<term>Adénocarcinome (génétique)</term>
<term>Adénocarcinome (métabolisme)</term>
<term>Adénocarcinome (traitement médicamenteux)</term>
<term>Adénocarcinome (ultrastructure)</term>
<term>Antinéoplasiques (pharmacologie)</term>
<term>Autophagie ()</term>
<term>Femelle</term>
<term>Humains</term>
<term>Hypoxie cellulaire ()</term>
<term>Inhibiteurs de protéines kinases (pharmacologie)</term>
<term>Interférence par ARN</term>
<term>Lignée cellulaire tumorale</term>
<term>Mâle</term>
<term>Phagosomes ()</term>
<term>Phagosomes (métabolisme)</term>
<term>Phagosomes (ultrastructure)</term>
<term>Poumon ()</term>
<term>Poumon (anatomopathologie)</term>
<term>Poumon (métabolisme)</term>
<term>Protéine-5 associée à l'autophagie</term>
<term>Protéines associées aux microtubules (antagonistes et inhibiteurs)</term>
<term>Protéines associées aux microtubules (génétique)</term>
<term>Protéines associées aux microtubules (métabolisme)</term>
<term>Protéines mutantes (antagonistes et inhibiteurs)</term>
<term>Protéines mutantes (métabolisme)</term>
<term>Protéines tumorales (antagonistes et inhibiteurs)</term>
<term>Protéines tumorales (génétique)</term>
<term>Protéines tumorales (métabolisme)</term>
<term>Récepteurs ErbB (antagonistes et inhibiteurs)</term>
<term>Récepteurs ErbB (génétique)</term>
<term>Récepteurs ErbB (métabolisme)</term>
<term>Résistance aux médicaments antinéoplasiques</term>
<term>Sujet âgé</term>
<term>Survie cellulaire</term>
<term>Transition épithélio-mésenchymateuse</term>
<term>Tumeurs du poumon (génétique)</term>
<term>Tumeurs du poumon (métabolisme)</term>
<term>Tumeurs du poumon (traitement médicamenteux)</term>
<term>Tumeurs du poumon (ultrastructure)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en">
<term>ErbB Receptors</term>
<term>Microtubule-Associated Proteins</term>
<term>Mutant Proteins</term>
<term>Neoplasm Proteins</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en">
<term>ErbB Receptors</term>
<term>Microtubule-Associated Proteins</term>
<term>Neoplasm Proteins</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en">
<term>ErbB Receptors</term>
<term>Microtubule-Associated Proteins</term>
<term>Mutant Proteins</term>
<term>Neoplasm Proteins</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en">
<term>Antineoplastic Agents</term>
<term>Protein Kinase Inhibitors</term>
</keywords>
<keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr">
<term>Poumon</term>
</keywords>
<keywords scheme="MESH" qualifier="antagonistes et inhibiteurs" xml:lang="fr">
<term>Protéines associées aux microtubules</term>
<term>Protéines mutantes</term>
<term>Protéines tumorales</term>
<term>Récepteurs ErbB</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en">
<term>Autophagy</term>
<term>Cell Hypoxia</term>
<term>Lung</term>
<term>Phagosomes</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en">
<term>Adenocarcinoma</term>
<term>Lung Neoplasms</term>
</keywords>
<keywords scheme="MESH" qualifier="genetics" xml:lang="en">
<term>Adenocarcinoma</term>
<term>Lung Neoplasms</term>
</keywords>
<keywords scheme="MESH" qualifier="génétique" xml:lang="fr">
<term>Adénocarcinome</term>
<term>Protéines associées aux microtubules</term>
<term>Protéines tumorales</term>
<term>Récepteurs ErbB</term>
<term>Tumeurs du poumon</term>
</keywords>
<keywords scheme="MESH" qualifier="metabolism" xml:lang="en">
<term>Adenocarcinoma</term>
<term>Lung</term>
<term>Lung Neoplasms</term>
<term>Phagosomes</term>
</keywords>
<keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr">
<term>Adénocarcinome</term>
<term>Phagosomes</term>
<term>Poumon</term>
<term>Protéines associées aux microtubules</term>
<term>Protéines mutantes</term>
<term>Protéines tumorales</term>
<term>Récepteurs ErbB</term>
<term>Tumeurs du poumon</term>
</keywords>
<keywords scheme="MESH" qualifier="pathology" xml:lang="en">
<term>Lung</term>
</keywords>
<keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr">
<term>Antinéoplasiques</term>
<term>Inhibiteurs de protéines kinases</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr">
<term>Adénocarcinome</term>
<term>Tumeurs du poumon</term>
</keywords>
<keywords scheme="MESH" qualifier="ultrastructure" xml:lang="en">
<term>Adenocarcinoma</term>
<term>Lung Neoplasms</term>
<term>Phagosomes</term>
</keywords>
<keywords scheme="MESH" xml:lang="en">
<term>Adenocarcinoma of Lung</term>
<term>Adult</term>
<term>Aged</term>
<term>Autophagy-Related Protein 5</term>
<term>Cell Line, Tumor</term>
<term>Cell Survival</term>
<term>Drug Resistance, Neoplasm</term>
<term>Epithelial-Mesenchymal Transition</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>RNA Interference</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr">
<term>Adulte</term>
<term>Adénocarcinome</term>
<term>Autophagie</term>
<term>Femelle</term>
<term>Humains</term>
<term>Hypoxie cellulaire</term>
<term>Interférence par ARN</term>
<term>Lignée cellulaire tumorale</term>
<term>Mâle</term>
<term>Phagosomes</term>
<term>Poumon</term>
<term>Protéine-5 associée à l'autophagie</term>
<term>Résistance aux médicaments antinéoplasiques</term>
<term>Sujet âgé</term>
<term>Survie cellulaire</term>
<term>Transition épithélio-mésenchymateuse</term>
<term>Tumeurs du poumon</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">Lung cancers harboring epidermal growth factor receptor (EGFR) mutations depend on constitutive activation of the kinase for survival. Although most EGFR-mutant lung cancers are sensitive to EGFR tyrosine kinase inhibitors (TKIs) and shrink in response to treatment, acquired resistance to TKI therapy is common. We demonstrate here that two EGFR-mutated lung adenocarcinoma cell lines, HCC827 and HCC4006, contain a subpopulation of cells that have undergone epithelial-to-mesenchymal transition and survive independent of activated EGFR. These EGFR-independent cancer cells, herein termed gefitinib-resistant (GR) cells, demonstrate higher levels of basal autophagy than their parental cells and thrive under hypoxic, reduced-serum conditions in vitro; this somewhat simulates the hypoxic environment common to cancerous tissues. We show that depletion of the essential autophagy gene, ATG5, by small interfering RNA (siRNA) or chloroquine, an autophagy inhibitor, markedly reduces GR cell viability under hypoxic conditions. Moreover, we show a significant elevation in caspase activity in GR cells following knockdown of ATG5. These results suggest that GR cells can evade apoptosis and survive in hostile, hypoxic environments with constant autophagic flux. We also show the presence of autophagosomes in some cancer cells from patient samples, even in untreated EGFR-mutant lung cancer tissue samples. Together, our results indicate that autophagy inhibitors alone or in combination with EGFR TKIs may be an effective approach for the treatment of EGFR-mutant lung cancers, where basal autophagy of some cancer cells is upregulated. </div>
</front>
</TEI>
<affiliations>
<list>
<country>
<li>Japon</li>
</country>
</list>
<tree>
<noCountry>
<name sortKey="Kameda, Yoichi" sort="Kameda, Yoichi" uniqKey="Kameda Y" first="Yoichi" last="Kameda">Yoichi Kameda</name>
<name sortKey="Koizume, Shiro" sort="Koizume, Shiro" uniqKey="Koizume S" first="Shiro" last="Koizume">Shiro Koizume</name>
<name sortKey="Matsukuma, Shoichi" sort="Matsukuma, Shoichi" uniqKey="Matsukuma S" first="Shoichi" last="Matsukuma">Shoichi Matsukuma</name>
<name sortKey="Miyagi, Yohei" sort="Miyagi, Yohei" uniqKey="Miyagi Y" first="Yohei" last="Miyagi">Yohei Miyagi</name>
<name sortKey="Nakamura, Yoshiyasu" sort="Nakamura, Yoshiyasu" uniqKey="Nakamura Y" first="Yoshiyasu" last="Nakamura">Yoshiyasu Nakamura</name>
<name sortKey="Nakayama, Haruhiko" sort="Nakayama, Haruhiko" uniqKey="Nakayama H" first="Haruhiko" last="Nakayama">Haruhiko Nakayama</name>
<name sortKey="Niki, Toshiro" sort="Niki, Toshiro" uniqKey="Niki T" first="Toshiro" last="Niki">Toshiro Niki</name>
<name sortKey="Oguni, Sachiko" sort="Oguni, Sachiko" uniqKey="Oguni S" first="Sachiko" last="Oguni">Sachiko Oguni</name>
<name sortKey="Saito, Haruhiro" sort="Saito, Haruhiro" uniqKey="Saito H" first="Haruhiro" last="Saito">Haruhiro Saito</name>
<name sortKey="Sekiguchi, Hironobu" sort="Sekiguchi, Hironobu" uniqKey="Sekiguchi H" first="Hironobu" last="Sekiguchi">Hironobu Sekiguchi</name>
<name sortKey="Yokose, Tomoyuki" sort="Yokose, Tomoyuki" uniqKey="Yokose T" first="Tomoyuki" last="Yokose">Tomoyuki Yokose</name>
<name sortKey="Yoshihara, Mitsuyo" sort="Yoshihara, Mitsuyo" uniqKey="Yoshihara M" first="Mitsuyo" last="Yoshihara">Mitsuyo Yoshihara</name>
</noCountry>
<country name="Japon">
<noRegion>
<name sortKey="Sakuma, Yuji" sort="Sakuma, Yuji" uniqKey="Sakuma Y" first="Yuji" last="Sakuma">Yuji Sakuma</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001116 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001116 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    ChloroquineV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:23938604
   |texte=   Enhanced autophagy is required for survival in EGFR-independent EGFR-mutant lung adenocarcinoma cells.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:23938604" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a ChloroquineV1 

Wicri

This area was generated with Dilib version V0.6.33.
Data generation: Wed Mar 25 22:43:59 2020. Site generation: Sun Jan 31 12:44:45 2021